Mucosal leishmaniasis and miltefosine.
Tuon
Felipe Francisco
FF
Amato
Valdir Sabbaga
VS
D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007891:Leishmania / Q000145:classification / Q000187:drug effects; D007897:Leishmaniasis, Mucocutaneous / Q000188:drug therapy* / Q000469:parasitology; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine